Clinical trials: Transitional Cell Carcinoma of Urinary Bladder
Urinary Bladder Cancer
Predictive Role of Microbiome in Patients With Urothelial Carcinoma
This study aims to establish the microbiota composition as a predictive tool for the response to the intravesical immunotherapy with Bacillus Calmette-Guérin (BCG) and 2 different chemotherapies schemes.
- Trial name
- NCT06675656
- Testing
- DNA extraction from urine, stool and biopsy. Isolation of serum and PBMC from peripheral blood.
- Volunteers
- 420 people
- Sponsor
- IRCCS San Raffaele
Urothelial Carcinoma
Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma
FORT-2 is designed to evaluate safety, efficacy, RP2D and PK of rogaratinib in combination with atezolizumab in patients with untreated FGFR-positive urothelial carcinoma.
- Trial name
- FORT-2 (NCT03473756)
- Testing
- Rogaratinib (BAY1163877), Atezolizumab
- Where
- 30 sites in United States, Austria and 6 more
- Volunteers
- 37 people
- Sponsor
- Bayer
Transitional Carcinoma of Urinary Bladder
Phase II Trial of Concurrent Administration of Intravesical BCG & Interferon in the Treatment and Prevention of Recurrence of Superficial Transitional Carcinoma of the Urinary Bladder
Phase II Trial of concurrent administration of intravesical BCG \& Interferon in the treatment and prevention of recurrence of superficial transitional carcinoma of the urinary bladder.
- Trial name
- NCT00539773
- Testing
- BCG, Interferon
- Volunteers
- 10 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Bladder Cancer
3-Dimensional Conformal Radiation Therapy in Treating Patients With Bladder Cancer Who Have Undergone Transurethral Resection of the Bladder
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal…
- Trial name
- NCT01124682
- Testing
- diagnostic cystoscopy, diffusion-weighted magnetic resonance imaging, implanted fiducial-based imaging
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Bladder Cancer
Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma
This is a single arm open- label phase II- trial evaluating safety and efficacy of paclitaxel and RAD001 in patients with metastatic urothelial bladder cancer who failed prior platin-based systemic therapy.
- Trial name
- RAD001 (NCT00933374)
- Testing
- paclitaxel, RAD001
- Where
- 6 sites in Germany
- Volunteers
- 28 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Bladder Urothelial Carcinoma, TURBT
Storz Professional Image Enhancement System Versus White Light Imaging Assisted TURBT for Treatment of NMIBC
Compare the therapeutic utility of SPIES assisted TURB with WLI assisted TURB in patients with non-muscle invasive bladder cancer.
- Conditions
- Bladder Urothelial Carcinoma, TURBT, Bladder Neoplasm, Cystoscopy
- Trial name
- NCT03138824
- Testing
- SPIES assisted TURBT, WLI assisted TURBT
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Mansoura University
Urothelial Cancer, Bladder Cancer
SU011248 for Platinum-Refractory Urothelial Cancer Evaluation Trial
The purpose of this study is to find out if SU011248 works and if it is safe in patients with advanced transitional cell carcinoma.
- Conditions
- Urothelial Cancer, Bladder Cancer, Adult
- Trial name
- SPRUCE (NCT00578526)
- Testing
- SU011248
- Where
- 5 sites in Canada
- Volunteers
- 64 people
- Sponsor
- AHS Cancer Control Alberta
Urinary Bladder Neoplasms
A Study to Evaluate Treatment Preferences for Japanese Participants With Muscle-invasive Urothelial Carcinoma of the Bladder
The main purpose of this study is to identify important treatment attributes for post-radical cystectomy (RC) treatment for participants with MIBC (Muscle-Invasive Bladder Cancer) and assess the relative importance of treatment…
- Trial name
- SNUGGLE (NCT05742867)
- Where
- United States
- Volunteers
- 115 people
- Sponsor
- Bristol-Myers Squibb
Bladder Neoplasms
Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder
Biochemotherapy (combined immunotherapeutic drugs and chemotherapeutic drugs) has shown virtue than that use chemical or biological drugs alone in the treatment of some malignant tumor.
- Trial name
- NCT00343356
- Testing
- Trement
- Volunteers
- 138 people
- Sponsor
- LanZhou University
Bladder Cancer
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer
The purpose of this study is to see whether 68Gallium PSMA-PET/CT scans are an effective way to detect sites of cancer in people with metastatic bladder cancer or skin cancer.
- Trial name
- NCT05562791
- Testing
- [68Ga]PSMA, PET/CT imaging
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Urothelial Carcinoma, Bladder Cancer
Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma
This research study is examining the effectiveness of pembrolizumab plus cryoablation or aveluma plus cryoablation on people with urothelial carcinoma, including bladder cancer, that has spread.
- Trial name
- NCT04701918
- Testing
- Pembrolizumab, Cryoablation, Avelumab
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Massachusetts General Hospital
Bladder Cancer
BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer
RATIONALE: Biological therapies, such as BCG, may stimulate the immune system in different ways and stop tumor cells from growing.
- Trial name
- NCT00352079
- Testing
- BCG vaccine, gefitinib, quality-of-life assessment
- Where
- 6 sites in Canada
- Volunteers
- 41 people
- Sponsor
- NCIC Clinical Trials Group
Bladder Cancer
A Proposed Tetra-modal Treatment Protocol for Muscle Invasive Urothelial Carcinoma of the Urinary Bladder
In Egypt, bladder cancer has been the most common cancer during the past 50 years. In 2002, Egypt's world-standardized bladder cancer incidence was 37/ 100,000, representing approximately 30,000 new cases each year.
- Trial name
- NCT05503563
- Testing
- terta modal bladder preservation
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Assiut University
Bladder Cancer
1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer
The goal of this part (Part 1) of this clinical research study is to learn about the safety of giving 2 doses of SCH 72105 (also known as rAd-IFN) directly into the bladder to patients with bladder cancer that has come back.
- Trial name
- NCT01162785
- Testing
- SCH 721015
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center
Urothelial Carcinoma
Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma
This is a single arm Phase II study with a safety run-in to identify the recommended phase II dose of the combination therapy of atezolizumab and guadecitabine.
- Trial name
- NCT03179943
- Testing
- Atezolizumab, Guadecitabine
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Fox Chase Cancer Center
Bladder Cancer, Urothelial Carcinoma
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
This Phase 3, single-arm, multicenter study was designed to evaluate the efficacy and safety of UGN-103, a novel formulation of UGN-102, instilled in the urinary bladder of patients with recurrent low-grade intermediate-risk…
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
- Trial name
- UTOPIA (NCT06331299)
- Testing
- UGN-103
- Where
- 48 sites in United States, Bulgaria and 5 more
- Volunteers
- 99 people
- Sponsor
- UroGen Pharma Ltd.
Bladder Cancer
Radiation Therapy With or Without Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy such as fluorouracil and mitomycin use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00024349
- Testing
- fluorouracil, mitomycin C, radiation therapy
- Where
- 27 sites in United Kingdom
- Volunteers
- 350 people
- Sponsor
- University Hospital Birmingham
Urinary Tract Urothelial Carcinoma
Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma
A majority of patients with bladder cancer have disease confined to the inner lining of the bladder. Patients with high risk features (high grade tumors, tumors invading into a deeper superficial layer) are routinely treated with…
- Trial name
- Sutent (NCT00794950)
- Testing
- Sunitinib
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- University of Michigan
Muscle-Invasive Bladder Cancer (MIBC), Urinary Bladder Cancer
Multi-Omics-Based Phase Ⅱ Trial of Trastuzumab Rezetecan Plus Camrelizumab for Perioperative Therapy in HER2-Positive Muscle-Invasive Urothelial Carcinoma
For patients with HER2-expressing muscle-invasive bladder cancer (MIBC), current neoadjuvant therapies dominated by platinum-based chemotherapy remain unsatisfactory with respect to improved clinical efficacy, pathological…
- Trial name
- NCT07639983
- Testing
- Trastuzumab Rezetecan plus Camrelizumab
- Volunteers
- 44 people
- Sponsor
- Sheng Tai
Muscle-Invasive Bladder Carcinoma, Bladder Cancer
Bladder Preservation or Cystectomy for MIBC
In this research study, investigators will assess whether it is feasible to use information from the genes of a tumor combined with evaluation of the tumor response to systemic therapy to determine if bladder sparing…
- Conditions
- Muscle-Invasive Bladder Carcinoma, Bladder Cancer, Urothelial Carcinoma
- Trial name
- NCT07821177
- Testing
- Gemzar, Cisplatin, Adrucil
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Dana-Farber Cancer Institute